Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). argenx SE's share price for the quarter that ended in Dec. 2024 was R$152.65. argenx SE's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 1,519 Mil. Therefore, argenx SE's market cap for the quarter that ended in Dec. 2024 was R$231,879 Mil.
argenx SE's quarterly market cap
increased
from Jun. 2024 (R$128,726 Mil) to Sep. 2024 (R$175,726 Mil) and
increased
from Sep. 2024 (R$175,726 Mil) to Dec. 2024 (R$231,879 Mil).
argenx SE's annual market cap
increased
from Dec. 2022 (R$109,476 Mil) to Dec. 2023 (R$109,702 Mil) and
increased
from Dec. 2023 (R$109,702 Mil) to Dec. 2024 (R$231,879 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. argenx SE's Enterprise Value for Today is R$185,787 Mil.
argenx SE Market Cap Historical Data
The historical data trend for argenx SE's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, argenx SE's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Market Cap distribution charts can be found below:
* The bar in red indicates where argenx SE's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
argenx SE's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (BSP:A1RG34) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
argenx SE Market Cap Related Terms
Thank you for viewing the detailed overview of argenx SE's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:A1RG34 has been successfully added to your 